31 results found.

Pulmonary Arterial Hypertension Clinical Trial using MK-8892

Merck Sharp & Dohme Corp. - Recruiting 18 years to 70 years.
- A Non-randomized, Single-panel, Open-label Trial to Study the Safety, Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial Hypertension.
MK-8892

Pulmonary Arterial Hypertension Clinical Trial using Slow-paced respiration therapy

University of Pennsylvania - Recruiting 21 years or older.
- Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension.
Slow-paced respiration therapy

Pulmonary Arterial Hypertension Clinical Trial

University of Arizona - Recruiting 18 years to 80 years.
- Comprehensive Characterization Of Right Ventricular Performance And Afterload In Patients With Pulmonary Arterial Hypertension Undergoing Initiation And Rapid Dose Escalation Of Treprostinil.

Pulmonary Arterial Hypertension Clinical Trial using Macitentan

Actelion - Recruiting 18 years to 80 years.
- A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument.
Macitentan

Pulmonary Arterial Hypertension Clinical Trial using Tadalafil- Tablet

Eli Lilly and Company - Recruiting 6 Months to 17 years.
- A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension.
Tadalafil- Tablet

Pulmonary Hypertension Clinical Trial using Ventavis (Iloprost, BAYQ6256)

Bayer - Recruiting 18 years or older.
- Study to Assess the Compliance of Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost.
Ventavis (Iloprost, BAYQ6256)

Pulmonary Hypertension Clinical Trial using Hydroxyurea

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Hydroxyurea in Pulmonary Arterial Hypertension.
Hydroxyurea

Pulmonary Arterial Hypertension Clinical Trial using Dual-energy computed tomography investigation

Medical University of Graz - Recruiting 18 years or older.
- Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography - Prospective Study.
Dual-energy computed tomography investigation

Severe Pulmonary Arterial Hypertension Clinical Trial using QTI571

Novartis - Recruiting 18 years or older.
- An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment.
QTI571

Pulmonary Arterial Hypertension Clinical Trial using MK-8892; Placebo for MK-8892

Merck Sharp & Dohme Corp. - Recruiting 18 years to 70 years.
- A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial Hypertension.
MK-8892; Placebo for MK-8892

Pulmonary Hypertension Clinical Trial using Carvedilol; Carvedilol placebo

The Cleveland Clinic - Recruiting 18 years to 65 years.
- Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure.
Carvedilol; Carvedilol placebo

Pulmonary Arterial Hypertension Clinical Trial using UT-15C (treprostinil diethanolamine)

United Therapeutics - Recruiting 18 years to 75 years.
- Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310.
UT-15C (treprostinil diethanolamine)

Pulmonary Arterial Hypertension Clinical Trial using Inhaled Nitrite

University of Pittsburgh - Recruiting 18 years to 78 years.
- A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension.
Inhaled Nitrite

Pulmonary Arterial Hypertension Clinical Trial using Ventavis (Iloprost, BAYQ6256)

Bayer - Recruiting 18 years or older.
- DAILY: Observational Description of Compliance for the Daily Ventavisr Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients.
Ventavis (Iloprost, BAYQ6256)

Hypertension, Pulmonary Clinical Trial using Tadalafil; Placebo

Eli Lilly and Company - Recruiting 6 Months to 18 years.
- A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension.
Tadalafil; Placebo

Pulmonary Arterial Hypertension, or Hypertension, Pulmonary Clinical Trial using Sildenafil

Pfizer - Recruiting 1 year to 17 years.
- A Phase 3, Multi-Center, Open-Label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension.
Sildenafil

Pulmonary Arterial Hypertension Clinical Trial using Beraprost Sodium 314d Modified Release Tablets; Placebo

Lung Rx - Recruiting 18 years to 80 years.
- A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvasor) in Subjects With Pulmonary Arterial Hypertension.
Beraprost Sodium 314d Modified Release Tablets; Placebo

Congenital Heart Disease, or Pulmonary Arterial Hypertension Clinical Trial using Sildenafil singly or in association with Bosentan

University of Sao Paulo General Hospital - Recruiting 2 Months or older.
- Combined Clinical and Surgical Approaches to Congenital Heart Disease Associated With Pulmonary Arterial Hypertension (PAH-CHD).
Sildenafil singly or in association with Bosentan

Vascular Disease Clinical Trial using ambrisentan

GlaxoSmithKline - Recruiting 18 years to 75 years.
- An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH).
ambrisentan

Pulmonary Arterial Hypertension Clinical Trial using PLX-PAD

United Therapeutics - Recruiting 18 years to 75 years.
- A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH.
PLX-PAD

Pulmonary Arterial Hypertension Clinical Trial using Spironolactone; Placebo

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension.
Spironolactone; Placebo

Pulmonary Arterial Hypertension, or Congenital Heart Disease Clinical Trial using observational

Actelion - Recruiting 18 years or older.
- Adult Congenital Heart Disease Quality Enhancement Research Initiative.
observational

Pulmonary Arterial Hypertension, HIV Infection, Congenital Heart Clinical Trial using skin biopsy; Blood Sample

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Auto-immunity and Prognosis of Pulmonary Arterial Hypertension.
skin biopsy; Blood Sample

Pulmonary Hypertension Clinical Trial using Right Heart Catheterization

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Evaluation of Prognostic Factors and Therapeutic Targets in Pulmonary Arterial Hypertension.
Right Heart Catheterization

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Clinical Trial using Rituximab; Placebo

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 75 years.
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Rituximab; Placebo

Pulmonary Hypertension Clinical Trial using Spironolactone; Placebo

Baylor College of Medicine - Recruiting 18 years or older.
- Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension.
Spironolactone; Placebo

Pulmonary Arterial Hypertension Clinical Trial using Carvedilol

The Hospital for Sick Children - Recruiting 8 years to 17 years.
- Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children.
Carvedilol

Pulmonary Arterial Hypertension Clinical Trial using udenafil; placebo

Dong-A Pharmaceutical Co., Ltd. - Recruiting 18 years or older.
- A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH).
udenafil; placebo

Pulmonary Arterial Hypertension, or Eisenmenger Syndrome Clinical Trial using respiratory and exercise therapy

University of Heidelberg - Recruiting 18 years to 80 years.
- Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life in Patients With Severe Associated Pulmonary Arterial Hypertension (APAH) as Part of a Congenital Heart Defect With / Without Eisenmenger's Syndrome.
respiratory and exercise therapy

Pulmonary Arterial Hypertension, Pulmonary Hypertension, or PAH W Clinical Trial using Sitaxsentan; Bosentan, Ambrisentan

West Penn Allegheny Health System - Recruiting N/A or older.
- Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes.
Sitaxsentan; Bosentan, Ambrisentan